Related Experiment Videos

Cutaneous T-cell lymphoma. New immunomodulators

N Apisarnthanarax1, M Duvic

  • 1Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

Dermatologic Clinics
|November 14, 2001
PubMed

During the most recent decades, much knowledge has been gained concerning the immunologic and pathologic mechanisms of CTCL. The development of immunomodulators aimed at correcting aberrations in immunology and cellular growth and differentiation reflects this increased understanding. This review of the currently available immune-response modifying drugs shows that recombinant forms of natural cytokines and retinoids can be developed with tolerable toxicity profiles and substantial efficacy. Although milestone drugs such as bexarotene have been approved by the FDA- for treatment of CTCL, other agents such as IL-12 may also have a place in treatment of the disease. Even though unapproved, IFN-alpha may be the most active single immunomodulating agent against CTCL. It seems that further delineation of CTCL cytokine profile changes and immunologic aberrations are key in developing effective immunomodulators that are able to reverse these alterations.

Related Concept Videos